Drag­on­fly preps clin­i­cal take­off, ink­ing a col­lab­o­ra­tion pact with MD An­der­son

Hav­ing lined up two mar­quee part­ners — Cel­gene and Mer­ck — and gained recog­ni­tion for its nat­ur­al killer plat­form tech­nol­o­gy, Drag­on­fly Ther­a­peu­tics is ready to roll with some of its own pro­grams.

The biotech up­start is ded­i­cat­ing $10 mil­lion to launch its first clin­i­cal stud­ies, which will be con­duct­ed in col­lab­o­ra­tion with the MD An­der­son Can­cer Cen­ter in Hous­ton and eval­u­at­ed in both sol­id tu­mor and hema­to­log­i­cal can­cers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER